ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 220 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2021. The put-call ratio across all filers is 1.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $239,996 | +17.7% | 6,732 | +52.3% | 0.04% | +50.0% |
| Q2 2023 | $203,895 | -79.9% | 4,420 | -68.4% | 0.03% | -82.9% |
| Q1 2022 | $1,015,000 | +42.4% | 13,982 | +87.0% | 0.18% | +41.1% |
| Q2 2021 | $713,000 | +216.9% | 7,478 | +277.9% | 0.12% | +313.3% |
| Q1 2021 | $225,000 | -85.6% | 1,979 | -82.5% | 0.03% | -85.3% |
| Q4 2020 | $1,567,000 | +15.9% | 11,317 | -31.2% | 0.20% | +17.9% |
| Q3 2020 | $1,352,000 | +37.0% | 16,450 | -25.9% | 0.17% | +32.1% |
| Q1 2020 | $987,000 | -14.4% | 22,207 | -17.7% | 0.13% | -31.4% |
| Q4 2019 | $1,153,000 | – | 26,995 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |